Akorn lays out $45M for Sunovion lung drug; Sanofi teams with Indian hospitals on diabetes clinics;

> Sunovion Pharmaceuticals said it would sell off rights to its respiratory drug Xoponex (levalbuterol) to Akorn ($AKRX) for $45 million. Release

> Sanofi ($SNY) teamed up with India's Apollo Hospitals on a diabetes-care program in India, delivered through a network of Apollo Sugar Clinics. Report

> Merck Serono tapped Hutchison China MediTech to market its beta blocker Ziac (bisoprolol HCl) in China. Report

> Pfizer Canada and WestJet launched a social media contest to raise awareness of anaphylaxis; Pfizer ($PFE) markets EpiPen in that country. Release

And Finally... Novo Nordisk ($NVO) and Diabetes UK started an awareness campaign, "Talk Hypos," to encourage diabetes patients to report hypoglycemia to their doctor or nurse. Release

Suggested Articles

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

Their merger isn't official yet, but a new logo is ready to go: Mylan and Pfizer's Upjohn unit unveiled new branding for their Viatris combo Thursday.

AbbVie's Allergan received a positive early ruling in its long-running trade secrets dispute with Evolus over a competitor to blockbuster Botox.